Ambrose Bierce

PATENT, n. A government-granted monopoly on the right to exclude others from using a discovery, usually issued to ensure that the discoverer may profit from the thing he did not create, but merely found, while the public pays for the privilege of being denied it.

The Progressive opponent speaks of the “enclosure of the commons” and the “final enclosure of the biological building blocks.” He is correct, in the manner that a man watching a house burn is correct to note the heat. The heat is real; the fire is not an accident, nor is it a tragedy in the sense of a sudden, unforeseen calamity. It is the intended outcome of a system designed to convert nature into inventory. Where the Progressive sees a moral injury - the theft of the commons - I see a mechanical function. The patent office is not a thief; it is a surveyor. It does not steal the land; it draws the line that makes theft legally permissible. To complain that the line is drawn is to misunderstand the purpose of the map.

The opponent argues that the waiting period - the silence of the laboratory - is a “holding pattern” where the market calculates and positions itself. He asks who benefits from uncertainty. He answers that it is rarely the researcher, but the entity holding the deed. This is a partial truth, obscured by the sentimentality of the word “entity.” The entity is not a person. It is a legal fiction, a shell constructed to absorb liability and distribute profit. The researcher is indeed irrelevant, not because he is exploited, but because he is replaceable. The patent does not reward the man who mixed the enzymes; it rewards the structure that can hold the exclusivity. The delay is not a pause in progress; it is the time required for the legal machinery to grind the organic into the inorganic. The enzyme is wet, messy, and alive. The patent is dry, precise, and dead. The transition from one to the other is the story.

Consider the parallel between the enclosure of the English fields in the eighteenth century and the patenting of recombinant DNA. The Enclosure Acts did not create new land. They did not make the soil more fertile. They merely transferred the right to use the land from the community to the landlord. The Progressive calls this theft. I call it definition. Before the fence, the grass was common. After the fence, the grass was property. The grass did not change. The definition did. So it is with the gene. The sequence of nucleotides exists in the wild. It exists in the lab. It exists in the patent office. In the first two places, it is biology. In the third, it is capital. The “enclosure” the opponent laments is not a new phenomenon; it is the final, logical extension of a property regime that has spent three centuries convincing us that ownership is a natural right rather than a legal construct.

The opponent’s error lies in his belief that the patent creates the incentive. This is the stated purpose, the left column of the ledger. The observed outcome, the right column, is the concentration of control. The patent does not incentivize innovation; it incentivizes litigation. It incentivizes the hoarding of knowledge. It ensures that the next step in the scientific ladder is owned by the man who owns the rung below it. The “hum of speculation” the opponent hears is not the sound of progress. It is the sound of valuation. The market is not calculating the utility of the drug; it is calculating the leverage of the monopoly.

What has disappeared from the Progressive narrative is the role of the state. The patent is not a private agreement. It is a public act. The government lends its coercive power to the corporation to exclude competitors. The “commons” was never free; it was merely unclaimed. The patent claims it. The benefit flows not to the “entity,” but to the alignment of legal and economic incentives that makes the entity possible. The researcher is a pawn. The patent is the board. The game is not biology; it is jurisdiction.

The story, when read through the operational definition, is not one of theft. It is one of translation. The language of life is being translated into the language of law. The meaning is lost in the translation, but the value is preserved. The Progressive mourns the loss of the commons. I observe the efficiency of the transfer. The commons is inefficient. It is chaotic. It is ungovernable. The patent is orderly. It is predictable. It is governable. The “human cost” the opponent cites is the friction of this transition. It is not a bug. It is the price of order.

Bois-style

There are two experiences of this event. Those with power experience the patent as a necessary engine of innovation, a mechanism to secure return on investment and spur the next wave of discovery. Those without power experience it as a foreclosure on the commons, a locking away of the building blocks of life behind a tollgate. The policy addresses only the first, treating the anxiety of the scientist as a market friction rather than a structural injustice.

The opponent speaks with considerable eloquence on the dread of the “tenants” awaiting eviction from the tools of their trade. This is the strongest point raised in the opposing statement: the recognition that the scientific community is not a monolith of privileged scholars but a fragmented marketplace of laborers whose livelihoods are subject to the whims of capital. I concede this entirely. The alienation of the worker from the means of production is a reality in the laboratory as it is in the factory. When the scientist finds that the very instruments of inquiry are subject to lease, the spirit of inquiry is indeed chilled. This is not merely a metaphor; it is the sociological reality of the modern research institution, where the pursuit of truth is increasingly subordinated to the pursuit of patentability.

However, where our frameworks diverge is in the diagnosis of the disease and the prescription for the cure. The opponent frames this as a transaction within “shadowed corridors,” suggesting a conspiracy of silence and exclusion that operates in the dark. I argue that the light of the Patent Office is blindingly bright, and that is the problem. The issue is not that the process is hidden, but that it is too visible, too legalistic, and too thoroughly integrated into the moral fabric of our commercial republic. To call it a conspiracy is to grant it a secretiveness it does not possess. It is a system that operates in broad daylight, justified by the very laws we have enacted to protect property. The silence is not one of secrecy, but of complicity.

We must look to the empirical record. In the late nineteenth century, when I surveyed the condition of Black Americans in Philadelphia, I did not find that poverty was maintained by secret societies or hidden plots. I found it maintained by the intersection of labor markets, housing discrimination, and legal structures that appeared neutral but functioned to exclude. Similarly, the patenting of recombinant DNA is not a shadowy plot but a structural outcome of a legal framework that treats intellectual property as absolute. The “interest” that maintains this order is not hidden; it has an address, and it is in the boardrooms of pharmaceutical corporations and the chambers of the courts that interpret the Constitution to favor the holder of the patent over the user of the gene.

The opponent’s anxiety about the “transfer of wealth from the public good to the private ledger” is well-founded. Yet, to view this solely as a commercial dispute is to miss the deeper civilisational implication. We are witnessing the commodification of the biological self. When the code of life becomes private property, the double consciousness of the scientist becomes acute: they are both the creator of knowledge and the servant of capital. They see the potential for healing; they also see the balance sheet. This tension is not a contradiction to be resolved by better regulation alone, but a fundamental conflict between the ethos of science, which demands open sharing, and the ethos of capitalism, which demands enclosure.

Consider the historical parallel of the enclosure movements in England. When common lands were fenced off, it was not done in secret. It was done through Acts of Parliament, with clear legal titles and public justification. The result was the displacement of the peasantry and the creation of a wage-labor force. Today, we are enclosing the genetic commons. The “tenants” the opponent describes are not merely scientists; they are the patients, the farmers, and the communities whose bodies and environments are the sites of this new extraction. The patent does not just restrict the scientist; it restricts the possibility of life itself from being a shared human heritage.

We must therefore reject the notion that this is a matter of “commercial anticipation” or “market friction.” It is a question of who owns the future. The view from behind the Veil reveals that the exclusion of certain voices from the decision-making process regarding these patents is not an accident. It is a feature of a system that values capital over community. The scientist’s dread is not just about job security; it is about the moral integrity of their work. When the tool is leased, the hand that wields it is no longer free.

The solution, therefore, cannot be found in appealing to the conscience of the patent holder or in hoping for a more benevolent interpretation of the law. It requires a reimagining of the relationship between knowledge and property. We must recognize that some things - like the code of life - should remain in the public domain, not because they are unprofitable, but because they are foundational to human dignity. The data shows that when knowledge is enclosed, innovation stagnates and inequality deepens. The prophetic voice insists that we cannot afford to let the ledger dictate the limits of our humanity. We must see the patent not as a reward for innovation, but as a barrier to the full realization of human potential. The silence of the scientific community is not anxious; it is waiting for us to break the spell of property and reclaim the commons.